♦ Molecular testing for prostate cancer in Israel. (30/07/2019)
♦ Onco tests for Thyroid Cancer in Israel. (23/07/2019)
♦ Review – Oncotests used in Israel. (24/06/2019)
♦ Papillary carcinoma of the thyroid (PTC) treatment in Israel. (24/01/2019)
♦ LDH analysis for melanoma treatment prognosis – study. (21/01/2019)
♦ New vaccinations requirements before treatment in Israel. (15/11/2018)
♦ Last stage cancer treatment in Israel. (06/02/2018)
♦ Triple Test Paradigm for precision cancer treatment in Israel. (08/01/2018)
♦ Personalized Cancer Prescreening in Israel – Creation of the Navigator Map of all potential treatment options, personally for each patient and his disease, outside of standard treatments. (03/01/2018)
♦ What is the difference between genetic and genomic testing? (01/01/2018)
♦ Immunotherapy for breast cancer in Israel. (26/12/2017)
♦ Opdivo (Nivolumab) – immunotherapy against cancer, continues to show good results and recommended by Israeli oncologists for adjuvant therapy and treatment of metastatic melanoma and lung cancer. (11/06/2017)
♦ Caris Molecular Intelligence – molecular test that defines the drugs effective on the cancer tumor, as well as those that are not effective. The performed at DNA, RNA and protein level for precision cancer treatment. (10/06/2017)
♦ Personalized lung cancer treatment in Israel. (13/09/2017)
♦ Innovative treatment of lymphoblastic leukemia (ALL) in Israel approved by FDA. (18/07/2017)
♦ Personalized breast cancer treatment in Israel. (10/07/2017)
♦ CANscript ™ (MitraBiotech) is a unique diagnostic that helps to select an effective treatment for severe forms of cancer individually for each patient and gives a reliable prognosis of the response to treatment. (04/23/2017)
New treatment options for breast cancer brain metastases (BCBM)
New clinical evidence suggests that patients live much longer even in cases of breast cancer brain metastases (BCBM) due to modern improved diagnostics, new initial treatment options and systemic methods, as well as a reduction in brain radiation exposure during radiotherapy.
FoundationOne CDx Ovarian Cancer testing checks an effectiveness of Lynparza targeted therapy
Now FoundationOne CDx Ovarian Cancer molecular oncotest is approved as a supplemental testing by the FDA when prescribing Lynparza — Olaparib. This targeted therapy is used as first-line maintenance treatment for metastatic ovarian cancer with BRCA 1/2 mutations.
Family history of melanoma increases risk of skin cancer by up to 74%
If one of first-degree relatives had a family history of melanoma, there is a significant risk of melanoma occurrence and skin malignant diseases in other family members, especially in the arms and legs. This is evidenced by a long-term study of dermatologists in an article published in the journal of the American Academy of Dermatology, new results of long-term study were announced.
Required genetic tests for all women diagnosed with breast cancer
According to the new recommendations of the American Society of Breast Surgeons (ASBrS), all women diagnosed with breast cancer are recommended to undergo genetic testis. These tests are performed regardless of the genetic mutations risk and heredity, in accordance with criteria approved by National Comprehensive Cancer Network(NCCN). Found mutations in women will directly affect treatment.
Treatment for various BRAF melanoma mutations
Molecular genetic tests allows to determine differences in BRAF gene mutations. It defines the treatment effectiveness for melanoma. New study revealed that there are differences between the BRAF genotypes in melanoma mutation – V600K and V600E. It leads to different responses for targeted therapy and immunotherapy.
Atezolizumab as a first line treatment for triple negative breast cancer
FDA approved under an accelerated program using Atezolizumab (Tecentriq) and Nab-Paclitaxel (a combination of immunotherapy with chemotherapy). This combination, as the first-line treatment, increases the overall survival in patients with triple negative breast cancer (TNBC). In fact, it is the first immunotherapy approved for this diagnosis.
Summary – the latest achievements and successful cancer treatment strategies in Israel and the world in 2018
2018 has shown progress in treatment of five rare complex oncological diseases. These year achievements were reported in the annual Journal Clinical Cancer Advances, the print publication of the American Society of Clinical Oncology (ASCO), as well as in the Journal of Clinical Oncology in January 2019.
mFOLFIRINOX – significant survival increase in pancreatic carcinoma treatment
In the new study, the combined treatment of Folfirinox or modified Folfirinox (mFOLFIRINOX) showed impressive results of patients survival with non-metastatic adenocarcinoma of the pancreatic duct (PDAC) after surgical resection, with good performance status.
Myths and truth about the occurrence of breast cancer (BC)
Nowadays on the Internet there are many myths about breast cancer, why it occurs and what provokes it. Below are the most frequently asked questions.
Breast cancer: 3 important findings to prevent metastases
The breast cancer disease takes second place on world statistics, and it is dangerous not only by the occurrence rates, but also further development of metastases. New research in comprehensive cancer studying was initiated in Lineberger Center at University Northern Carolina. In this research was found genetic key with an explanation how breast cancer appear and spread.
The Journal of Clinical Investigation published the analysis of scientific geneticists who studied a difference between primary, diagnosed for the first time breast cancer and its metastases. The understanding of development of secondary cancer as researchers consider, will allow to explain cancer emergence. Insight into an essence of these processes opens new opportunities for oncologists on treatment and prevent to develop a metastatic breast cancer.